Study: Treatment for Follicular Lymphoma Patients Must be Individualized
source: pixabay.com

Study: Treatment for Follicular Lymphoma Patients Must be Individualized

A recent study examined three different follicular lymphoma (FL) patients to try to better understand how the disease presents differently for different individuals. Ultimately, this study has reiterated the importance…

Continue Reading Study: Treatment for Follicular Lymphoma Patients Must be Individualized
AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS
source: pixabay.com

AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS

  AI Therapeutics is a biotechnology company that uses artificial intelligence to match drugs to indications. They do so through the use of their algorithm, Guardian Angel. This algorithm has…

Continue Reading AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS
Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma
source: pixabay.com

Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma

According to a publication from Benzinga, the U.S. Food and Drug Administration has granted Breakthrough Therapy status to Bayer's relapsed follicular lymphoma drug Aliqopa (copanlisib) for the treatment of marginal…

Continue Reading Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma

Study Shows Impressive Results Using 3 Drug Combo in High-Risk Follicular Lymphoma

Massimo Federico, MD, director of the medical oncology unit at the University of Modena and Reggio Emilia, Italy, was quoted in Cancer Network as saying that “Achieving a complete clinical and…

Continue Reading Study Shows Impressive Results Using 3 Drug Combo in High-Risk Follicular Lymphoma

Researchers Find the Future of Ofatumumab in Treating Follicular Lymphoma is Questionable

Ofatumumab as a Single Agent  Results of ofatumumab administered as a single agent with an extended induction (initial treatment) brought about a high response rate and it was well tolerated among follicular…

Continue Reading Researchers Find the Future of Ofatumumab in Treating Follicular Lymphoma is Questionable
The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
qimono / Pixabay

The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)

The United States Food and Drug Administration has approved Copiktra™ (duvelisib). The drug is now approved as a treatment for adult patients diagnosed with refractory or relapsed chronic lymphocytic leukaemia…

Continue Reading The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
Close Menu